News

LRF Launches Multi-Million Dollar Global Initiative to Drive Follicular Lymphoma Clinical Research

Established through the generosity of the Peykoff Family and Niagara Cares, the $10 million Initiative is poised to transform the follicular lymphoma treatment landscape for tens of thousands of patients by harnessing LRF’s unique resources, convening the world’s experts in follicular lymphoma research and patient care, and driving direct investment in clinical research.

Buildings and Landmarks Join LRF to Light Red and Raise Awareness for Blood Cancer Awareness Month

The tenth anniversary of the Lymphoma Research Foundation’s Blood Cancer Awareness Month initiative expected to reach millions.

Finding Cures Starts With You: LRF to Honor Heroes in Oncology at 25th Anniversary Virtual Gala

Foundation to Celebrate Achievements of Honorees AstraZeneca, Thomas M. Habermann, MD and Heroes Among the Lymphoma Community

Patient Perspectives: Using Consistent Terminology for Biomarker and Germline Genetic Testing

A multi-stakeholder working group recommends consistent biomarker, genetic and genomic testing terminology for patient education and clinical care.

Finding Cures Starts Here: The Lymphoma Research Foundation Reaches 25-Year Milestone

LRF celebrates 25 years of innovation and progress with global awareness and fundraising campaign.

Meet the 2020 Career Development Award and Postdoctoral Fellowship Grantees

Projects awarded from this year’s class of CDA and Postdoctoral Fellows include early clinical trials of novel therapies, investigations into the biology of Hodgkin lymphoma and aggressive non-Hodgkin lymphomas, and new mechanisms for chimeric antigen receptor (CAR) T cell therapy.

Linked By Lymphoma: A Story of Friendship Through the Lymphoma Support Network

Five years ago, Jacqueline Gates and John Groskopf were strangers; they would soon discover they shared a rare similarity that would connect them forever.

U.S. Food and Drug Administration Approves Tafasitamab-cxix (MONJUVI) for Diffuse Large B-cell Lymphoma (DLBCL)

On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…

Global Public Relations Executive Joins Lymphoma Research Foundation Board of Directors

Lymphoma Research Foundation Elects Allison+Partners Co-Founder Scott Pansky to Esteemed Board

LRF CEO Meghan Gutierrez Appointed to American Board of Internal Medicine Specialty Board

The American Board of Internal Medicine (ABIM) has ABIM has 12 Specialty Boards - one for all disciplines solely sponsored and administered by ABIM. The Specialty Boards are where the frontline work at the discipline-specific level is done.

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.